suzhou, china, november 2, 2021 - alphamab oncology (stock code: 9966.hk), appoints mr. jing han as chief commercial officer. mr. han will be responsible for the company's commercialization strategy and execution, and report to dr. ting xu, chairman & ceo of alphamab oncology.
mr. jing han has over 20 years experiences in pharmaceutical sales and marketing. he has served both in world-renowned multinational pharmaceutical companies including msd, boehringer ingelheim, astrazeneca, bayer, roche, and in chinese innovative biopharmaceutical companies such as shanghai junshi biosciences co., ltd. he has accumulated rich experience in building and leading commercialization teams, formulating and executing commercialization strategies. before joining alphamab oncology, mr. han served as senior vice president of genor biopharma, responsible for the establishment of its marketing team and various commercialization matters before listing.
dr. ting xu, chairman and ceo of alphamab oncology, commented, “welcome mr. jing han to alphamab oncology. since the establishment of the company, we are striving to become a fully integrated global leading biopharmaceutical company. the company is about to launch its first product, and we plan to submit the bla for our core product kn046 next year. mr. jing han has extensive commercialization experience both in multinational and local pharmaceutical companies, with a proven record of delivering innovative products to benefit patients in need. we believe that his joining will accelerate the commercialization of kn046 and other blockbuster products under development.”
mr. jing han, chief commercial officer of alphamab oncology, commented, “in the ever-changing landscape of china biotech innovation, alphamab oncology is undoubtedly a bright star. under the leadership of chairman dr. ting xu, the company has developed proprietary multifunctional antibody platforms, integrating excellent r&d and production technologies. i am very much drawn to the mission of the company, to make cancer manageable and curable, and its strategy, in china for the world. i believe that alphamab oncology will offer many first-in-class and best-in-class products in future to benefit patients at home and abroad. i am looking forward to working together with my colleagues to build a better future.”
mr. jing han graduated from the department of clinical medicine of shanghai second medical university (currently known as shanghai jiao tong university school of medicine) in 1996 and began to work as a general surgeon until he chose to join msd in 1998 and started his career in pharmaceutical companies for more than 20 years. in 2018, mr. jing han received his executive master degree of business administration from china europe international business school.
about alphamab oncology
alphamab oncology is focusing on innovation, production and commercialization of anti-tumor drugs. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.
alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a covid-19 bispecific antibody. four products have advanced into phase i-iii clinical trials or pre-marketing stage in china, the united states, japan and australia. the bla for envafolimab (kn035) has been accepted and granted priority review by the national medical products administration (nmpa).
the company also has state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards and a complete quality system which has passed the on-site inspection of a european union qualified person. alphamab oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in china and around the world.
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
